The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma

Istituto Ortopedico Rizzoli1 site in 1 country1,000 target enrollmentApril 2, 2021

ConditionsSarcoma, Ewing

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Sarcoma, Ewing
Sponsor: Istituto Ortopedico Rizzoli
Enrollment: 1000
Locations: 1
Primary Endpoint: 5-year survival
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Extraction of laboratory data from blood tests prior to surgical and chemotherapy and other histological, clinical and instrumental data related to the patient's history from the digitized medical Digitized medical records and analysis of the same. The medical records of 1000 patients from January 1, 2000, until December 31, 2020

Registry

clinicaltrials.gov

Start Date

April 2, 2021

End Date

July 1, 2021

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Istituto Ortopedico Rizzoli

Responsible Party

Principal Investigator

Costantino Errani

Principal Investigator

Istituto Ortopedico Rizzoli

Eligibility Criteria

Inclusion Criteria

•Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis;
•Patients with age ≥ 2 years;
•Minimum follow-up duration of 2 years;
•Medical records, complete blood work and instrumental examinations; Regular follow-up.

Exclusion Criteria

•Patients with Ewing's sarcoma or osteosarcoma who have received medical treatment (surgery radiotherapy or chemotherapy) in other institutions prior to admission to the Rizzoli Orthopaedic Institute.